Active Ingredient History

  • Now
Setipiprant (INN; developmental code names ACT-129968, KYTH-105) is an investigational drug developed for the treatment of asthma and scalp hair loss. It was originally developed by Actelion and acts as a selective, orally available antagonist of the prostaglandin D2 receptor 2 (DP2). The drug is being developed as a novel treatment for male pattern baldness by Allergan.   Wikipedia

  • SMILES: OC(=O)Cn1c2CCN(Cc2c3cc(F)ccc13)C(=O)c4cccc5ccccc45
  • Mol. Mass: 402.43
  • ALogP: 4.22
  • ChEMBL Molecule:
More Chemistry
2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1h-pyrido(4,3-b)indol-5(2h)-yl)acetic acid | act-129968 | kyth-105 | setipiprant


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue